Kam LY - Search Results

1

Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease.

Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang H. Abreu MT, et al. Among authors: kam ly. Gastroenterology. 2002 Sep;123(3):679-88. doi: 10.1053/gast.2002.35393. Gastroenterology. 2002. PMID: 12198692

2

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.

Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. Dubinsky MC, et al. Among authors: kam ly. Gastroenterology. 2002 Apr;122(4):904-15. doi: 10.1053/gast.2002.32420. Gastroenterology. 2002. PMID: 11910342 Clinical Trial.

3

Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease.

Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, Yang H, Hu B, Lin YC, Keenan G, Price J, Landers CJ, Adams JS, Targan SR. Abreu MT, et al. Among authors: kam ly. J Clin Gastroenterol. 2006 Jan;40(1):55-63. doi: 10.1097/01.mcg.0000190762.80615.d4. J Clin Gastroenterol. 2006. PMID: 16340635

4

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB, Targan SR. Vasiliauskas EA, et al. Among authors: kam ly. Gastroenterology. 1999 Dec;117(6):1278-87. doi: 10.1016/s0016-5085(99)70277-5. Gastroenterology. 1999. PMID: 10579968 Clinical Trial.

5

Outcome of cytomegalovirus infections in patients with inflammatory bowel disease.

Papadakis KA, Tung JK, Binder SW, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. Papadakis KA, et al. Among authors: kam ly. Am J Gastroenterol. 2001 Jul;96(7):2137-42. doi: 10.1111/j.1572-0241.2001.03949.x. Am J Gastroenterol. 2001. PMID: 11467645

6

Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease.

Hassard PV, Vasiliauskas EA, Kam LY, Targan SR, Abreu MT. Hassard PV, et al. Among authors: kam ly. Inflamm Bowel Dis. 2000 Feb;6(1):16-20. doi: 10.1097/00054725-200002000-00003. Inflamm Bowel Dis. 2000. PMID: 10701145

7

Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Vasiliauskas EA, et al. Among authors: kam ly. Gut. 2000 Oct;47(4):487-96. doi: 10.1136/gut.47.4.487. Gut. 2000. PMID: 10986208 Free PMC article.

8

TNF-alpha antagonists for the treatment of Crohn's disease.

Kam LY, Targan SR. Kam LY, et al. Expert Opin Pharmacother. 2000 May;1(4):615-22. doi: 10.1517/14656566.1.4.615. Expert Opin Pharmacother. 2000. PMID: 11249506 Review.

9

An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy.

Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. Dubinsky MC, et al. Among authors: kam ly. Inflamm Bowel Dis. 2001 Aug;7(3):181-9. doi: 10.1097/00054725-200108000-00001. Inflamm Bowel Dis. 2001. PMID: 11515842 Clinical Trial.

10

Cytokine-based therapies in inflammatory bowel disease.

Kam LY, Targan SR. Kam LY, et al. Curr Opin Gastroenterol. 1999 Jul;15(4):302-7. doi: 10.1097/00001574-199907000-00005. Curr Opin Gastroenterol. 1999. PMID: 17023962

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters